dict.md logo
Wählen Sie die gewünschten Sprachen
AUSWÄHLEN >>
Englisch
Portugiesisch
Norwegisch
Rumänisch
Niederländisch
 
Weitere Sprachen hinzufügen:
Add all languages
Anzeigen:
Übersetzungen
 
0 Übersetzungen
 
Definition
 
enEnglisch
ISIS 5132 Definition: A substance that is being studied in the treatment of cancer.
ISIS 5132 Definition: A synthetic, 20-base antisense oligodeoxynucleotide that hybridizes to c-raf kinase messenger RNA. ISIS 5132 has been shown to specifically suppress Raf-1 expression both in vitro and in vivo. Raf-1 serine/threonine kinase functions as a critical effector of Ras-mediated signal transduction; constitutive activation of this pathway directly contributes to malignant transformation. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42994&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42994&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2721" NCI Thesaurus)
ISIS 5132 Definition: A synthetic, 20-base antisense oligodeoxynucleotide that hybridizes to c-raf kinase messenger RNA. ISIS 5132 has been shown to specifically suppress Raf-1 expression both in vitro and in vivo. Raf-1 serine/threonine kinase functions as a critical effector of Ras-mediated signal transduction; constitutive activation of this pathway directly contributes to malignant transformation. (NCI04)
ISIS 3521 Definition: A substance that is being studied in the treatment of cancer.
ISIS 3521 Definition: A synthetic phosphorothioate oligodeoxynucleotide. As an antisense molecule, ISIS 3521 hybridizes to the 3-untranslated region of the human protein kinase C (PKC-alpha) mRNA, thereby inhibiting PKC-alpha expression and growth of PKC-alpha-dependent tumor cells. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42953&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42953&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1788" NCI Thesaurus)
ISIS 3521 Definition: A synthetic phosphorothioate oligodeoxynucleotide. As an antisense molecule, ISIS 3521 hybridizes to the 3-untranslated region of the human protein kinase C (PKC-alpha) mRNA, thereby inhibiting PKC-alpha expression and growth of PKC-alpha-dependent tumor cells. (NCI04)
ISIS 2503 Definition: A substance that is being studied in the treatment of cancer.
ISIS 2503 Definition: A synthetic oligodeoxynucleotide. Functioning as an anti-sense agent, it hybridizes to the translation initiation region of the human mRNA for the oncogene H-Ras. ISIS 2503 selectively inhibits the expression of H-Ras, and may inhibit the growth of some Ras-dependent tumor cells. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37795&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37795&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2024" NCI Thesaurus)
ISIS 2503 Definition: A synthetic oligodeoxynucleotide. Functioning as an anti-sense agent, it hybridizes to the translation initiation region of the human mRNA for the oncogene H-Ras. ISIS 2503 selectively inhibits the expression of H-Ras, and may inhibit the growth of some Ras-dependent tumor cells. (NCI04)
OGX-011 Definition: A mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. OGX-011 inhibits testosterone-repressed prostate message-2 (TRPM-2). Administration of OGX-011 abrogates the anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death. TRPM-2 is an anti-apoptotic clusterin that is overexpressed by prostate cancer cells and is associated with chemoresistance. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=271195&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=271195&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1055" NCI Thesaurus)
 
Beispiele
 

We examined the association of seven single nucleotide polymorphisms (SNPs) across the LTA gene, and their related haplotypes, with risk of myocardial infarction (MI) in the International Study of Infarct Survival (ISIS) case-control study involving 6,928 non-fatal MI cases and 2,712 unrelated controls.

Robert Clarke et al.

PLoS Genetics 2 (7), 01 Jul 2006

The results of the ISIS study were considered in the context of six previously published studies that had assessed this association, and this meta-analysis found no significant association with CHD risk using a recessive model and only a modest association using a dominant model (with narrow confidence intervals around these risk estimates).

Robert Clarke et al.

PLoS Genetics 2 (7), 01 Jul 2006

These findings emphasize the need for large-scale studies to have sufficient power to detect associations of genetic variants with CHD risk and the need for replication of any such associations in independent studies of even larger size. citation Clarke R, Xu P, Bennett D, Lewington S, Zondervan K, et al. (2006) Lymphotoxin-α gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study.

Robert Clarke et al.

PLoS Genetics 2 (7), 01 Jul 2006

We have examined the association between seven SNPs in the LTA gene, and their related haplotypes, with risk of MI in the large ISIS [ 13 ] case-control study, and then included it in a meta-analysis of all previously published reports on this association.

Robert Clarke et al.

PLoS Genetics 2 (7), 01 Jul 2006

Table 1 shows the location and relevant characteristics of the seven SNPs in the LTA gene on chromosome 6p21 that were examined in the International Study of Infarct Survival (ISIS) study.

Robert Clarke et al.

PLoS Genetics 2 (7), 01 Jul 2006

7 weitere Beispiele >>
Publikationen
 
0 Publikationen